A Review on Gullian Barre Syndrome and its Association with COVID 19

Abstract

Guillain-Barré syndrome (GBS) is an immune-mediated disease that affects peripheral nerves and can lead to life-threatening consequences. It affects around 10000 people per year worldwide. Since the outbreak of acute respiratory syndrome coronavirus-2 (sar-cov-2) the incidence of GBS has been increased with a fatality rate of 4-7%. The exact association between the Sar-cov-2 and GBS is still unknown. GBS commonly presents after viral infections such as influenza virus, campylobacter jejuni, and zika virus. Clinical recognition of SC2-GBS is required in order to administer appropriate treatment on time and enhance the overall output of the infection. In most of the conditions patient was treated with intravenous immunoglobulins and outcome was seen within eight weeks of treatment. less outcome was seen in older age in line with previous findings for both GBS and COVID-19. Studies should be conducted to compare patients associated with GBS to those with concurrent non-COVID-19 GBS to see if the incidence of GBS is higher in those with COVID-19.
 Keywords: Guillian-Barre syndrome, COVID-19, SAR-COV2